<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071119</url>
  </required_header>
  <id_info>
    <org_study_id>22301</org_study_id>
    <secondary_id>K01AA026874</secondary_id>
    <nct_id>NCT04071119</nct_id>
  </id_info>
  <brief_title>Alcohol and Cigarette Craving During Oxytocin Treatment</brief_title>
  <official_title>The Neural Mechanisms Associated With Alcohol and Cigarette Craving in Alcohol Use Disorder Smokers During Oxytocin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed research seeks to examine the behavioral and neural substrates of intranasal&#xD;
      oxytocin compared to placebo on alcohol cue-induced alcohol and cigarette craving smokers&#xD;
      with an alcohol use disorder (AUD). Non treatment-seeking smokers with an AUD will be&#xD;
      recruited to participate in a between-subjects, placebo-controlled, randomized pilot&#xD;
      functional magnetic resonance imaging (fMRI) study. Participants will undergo an fMRI scan in&#xD;
      conjunction with an alcohol-olfactory cue-reactivity task. Secondary assessments will include&#xD;
      alcohol and cigarette craving, alcohol and cigarette consumption, physiological measures&#xD;
      (heart rate and blood pressure) and mood measures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>1 day</time_frame>
    <description>average alcohol craving during the cue-reactivity task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cigarette craving</measure>
    <time_frame>1 day</time_frame>
    <description>average cigarette craving during the cue-reactivity task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activity</measure>
    <time_frame>1 day</time_frame>
    <description>BOLD response when comparing alcohol to neutral cues during fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol and cigarette consumption</measure>
    <time_frame>5-7 days</time_frame>
    <description>alcohol and cigarette consumption assessed by the Timeline Followback</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days</description>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants administer the placebo (40 IU) twice a day for 5 - 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female&#xD;
&#xD;
          2. 18 to 55 years of age&#xD;
&#xD;
          3. meet criteria for Alcohol Use Disorder DSM-5 diagnosis&#xD;
&#xD;
          4. meet the National Institute on Alcohol Abuse and Alcoholism criteria for&#xD;
             heavy-drinking&#xD;
&#xD;
          5. smoke at least ≥5 cigarettes/day for at least a year, verified with breath carbon&#xD;
             monoxide level &gt; 5 ppm&#xD;
&#xD;
          6. in good health as confirmed by medical history, physical examination and lab tests&#xD;
&#xD;
          7. willing to take the medication and adhere to the study procedures&#xD;
&#xD;
          8. breath alcohol concentration (BrAC) = 0.00 at each visit&#xD;
&#xD;
          9. understand informed consent and questionnaires written in English at an 8th grade&#xD;
             level&#xD;
&#xD;
         10. right-handedness&#xD;
&#xD;
         11. normal to normal-corrected vision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. positive urine test for pregnancy&#xD;
&#xD;
          2. women who are breast-feeding&#xD;
&#xD;
          3. body mass index &gt; 40&#xD;
&#xD;
          4. current or prior history of any clinically significant disease, cardiovascular,&#xD;
             respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders,&#xD;
             positive hepatitis or HIV test that could affect study participation, as determined by&#xD;
             the study physician&#xD;
&#xD;
          5. history of suicide attempts&#xD;
&#xD;
          6. current diagnosis of substance dependence other than alcohol, nicotine or cannabis as&#xD;
             assessed by self-report and urine toxicology screen at baseline&#xD;
&#xD;
          7. current use of psychoactive medications or any medication that may interact with&#xD;
             oxytocin&#xD;
&#xD;
          8. history of hypersensitivity to oxytocin&#xD;
&#xD;
          9. chronic rhinitis or sinusitis&#xD;
&#xD;
         10. clinically significant electrolyte abnormalities&#xD;
&#xD;
         11. vasoconstricting medications or prostaglandins&#xD;
&#xD;
         12. clinically significant medical abnormalities: unstable hypertension, bilirubin &gt;150%&#xD;
             of the upper normal limit (UNL), ALT/AST &gt;500% the UNL, creatinine clearance ≤60&#xD;
             dl/min)&#xD;
&#xD;
         13. significant alcohol withdrawal symptoms, defined as a CIWA-Ar &gt; 8&#xD;
&#xD;
         14. positive urine drug screen at baseline for any excluded substances&#xD;
&#xD;
         15. individuals seeking treatment&#xD;
&#xD;
         16. meets DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other&#xD;
             psychoses&#xD;
&#xD;
         17. claustrophobia&#xD;
&#xD;
         18. any contraindications with the MRI machine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimberly Goodyear, Ph.D.</last_name>
    <phone>401-863-6626</phone>
    <email>kimberly_goodyear@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Alcohol and Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Goodyear, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Carolina L Haass-Koffler, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert M Swift, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Kimberly Goodyear</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>craving</keyword>
  <keyword>alcohol use disorder</keyword>
  <keyword>smoking</keyword>
  <keyword>cigarettes</keyword>
  <keyword>drinking</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>cue-reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

